Enhancing the rational use of new medicines across European health care systems.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
   Article
2. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.Frontiers in pharmacology · 2022
   Article
3. European collaborations on medicine and vaccine procurement.Bulletin of the World Health Organization · 2021
   Article
4. Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020
   Review
5. Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.Frontiers in pharmacology · 2020
   Article
6. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018
   Review
7. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Frontiers in pharmacology · 2017
   Review
8. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.PharmacoEconomics · 2015
   Review
9. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.BMC health services research · 2015
   Observational
10. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.Frontiers in pharmacology · 2014
    Review
11. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.Frontiers in pharmacology · 2014
    Review
12. Personalizing health care: feasibility and future implications.BMC medicine · 2013
    Review
13. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Frontiers in pharmacology · 2013
    Article
14. Implementing a statin switching programme in primary care: patients' views and experiences.British journal of clinical pharmacology · 2012
    Article
15. Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Frontiers in pharmacology · 2012
    Article
16. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Pharmaceuticals (Basel, Switzerland) · 2010
    Review
17. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC health services research · 2010
    Review
18. Forecasting drug utilization and expenditure in a metropolitan health region.BMC health services research · 2010
    Article
19. Policies to enhance prescribing efficiency in europe: findings and future implications.Frontiers in pharmacology · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as